Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis

登録ユーザーのみが記事を翻訳できます

ログインサインアップ

リンクがクリップボードに保存されます

状態完了

スポンサー

University of Siena

臨床試験: NCT03911570

BioSeek: nct03911570

キーワード

概要

The objective of this study is to retrospectively evaluate the symptomatic effects of crystalline glucosamine sulfate (GS), prescribed for the actually approved indication of knee OA, in addition to conventional therapy, in comparison to the conventional therapy alone in patients with primary hand osteoarthritis (HOA).This is a 6-months retrospective comparative study including patients with concomitant knee and primary HOA, according to the ACR criteria. To be eligible the patients had to present clinical symptoms of hand OA for at least 3 months, defined as global hand pain score superior to 40 mm on a 0-100 Visual Analogue Scale (VAS) and a Functional Index for Hand Osteoarthritis (FIHOA) score of at least 6. Furthermore, the patients have had a radiographic evidence of HOA within the previous 6 months with a Kellgren-Lawrence score of II-III. The participants are stratified into two groups based on whether or not crystalline GS at the daily dose of 1500 mg was added to the conventional therapy for HOA, including exercise, acetaminophen and non steroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase (COX)-2 inhibitors. Primary outcome measures are the difference between the two groups in the change of VAS pain and in the FIHOA, from baseline after 6 months. Secondary outcomes were health assessment questionnaire (HAQ), medical outcomes study 36-item short form (SF-36) and symptomatic drugs consumption.

日付

最終確認済み:	03/31/2019
最初に提出された:	04/08/2019
提出された推定登録数:	04/08/2019
最初の投稿:	04/10/2019
最終更新が送信されました:	04/09/2019
最終更新日:	04/11/2019
実際の研究開始日:	08/31/2018
一次完了予定日:	12/31/2018
研究完了予定日:	01/31/2019

状態または病気

Hand Osteoarthritis

介入/治療

Drug: Glucosamine Sulfate

段階

アームグループ

腕	介入/治療
Glucosamine Sulfate Group (GS Group) GS Group is treated for at least 6 consecutive months with a single daily dose of 1500 mg of crystalline GS (powder sachets), in addition to conventional therapy.
Control Group Control Group receive only usual care therapy. The conventional therapy includes exercise for HOA and treatment with acetaminophen or oral NSAIDs or COX-2 inhibitors (150 mg Diclofenac tablets, 20 mg Piroxicam tablets, 550 mg Naproxen tablets, 200 mg Aceclofenac, 600 mg Ibuprofen tablets, 200 mg Celecoxib tablets, 60 mg Etoricoxib tablets).

適格基準

研究の対象となる年齢	45 Years に 45 Years
研究に適格な性別	All
サンプリング方法	Probability Sample
健康なボランティアを受け入れる	はい
基準	Inclusion Criteria: - Mono or bilateral primary HOA and concomitant knee OA, according to the American College of Rheumatology (ACR) criteria - Treatment for at least 6 consecutive months with crystalline GS at the daily dose of 1500 mg in addition to the conventional therapy or with usual care alone. - HOA symptoms duration for at least 3 months defined as global hand pain score superior to 40 mm on a 0-100 VAS and a FIHOA score of at least 6. - Radiographic evidence of HOA within the previous 6 months with a radiological score of II-III (using the Kellgren method). Exclusion Criteria: - Erosive Osteoarthritis of the hand - Medical history of any inflammatory joint disease, septic arthritis, previous articular fracture of the concerned joints, monarticular post-traumatic OA of the finger, a history or the presence of any other rheumatic diseases that could cause secondary OA, such as hemochromatosis. - Ongoing therapy with opioid analgesics and any kind of topical treatment - Therapy with SYSADOAs other than GS, steroids by any route of administration and intra-articular injection of any joint with hyaluronic acid during the previous 6 months. - Contraindications or special warnings for GS presented in the data sheet.

結果

主な結果の測定

1. Difference between the two groups in the change of the patient's assessment of global hand pain on a 0- 100 mm Visual Analogue Scale [Basal time; one month; three months; six months]

0-100 mm scale with 0 representing the absence of pain

二次的な結果の測定

1. Difference between the two groups in the change of the Functional Index for Hand Osteoarthritis (FIHOA) score [Basal time; one month; three months; six months]

The FIHOA score represents a quantitative measure of functional disability of the hands; it contains 10 items and is an investigator-administered questionnaire. Patients are asked to answer each item using a four-point Likert scale: 0 = possible without difficulty, 1 = possible with slight difficulty, 2 = possible with considerable difficulty, 3 = impossible; the range of scores is 0-30 and the highest values indicate the worst functionality. The validate Italian version of FIHOA is used for the present study.

2. Health Assessment Questionnaire (HAQ) [Basal time; one month; three months; six months]

HAQ is a self administered questionnaire developed to measure disability consisting of 8 sections: dressing arising, eating, walking, hygiene, reach, grip, and activities and ranging from 0 to 3 with a higher score corresponding to worse disability

3. Medical Outcomes Study 36-Item Short Form (SF-36) [Basal time; one month; three months; six months]

SF-36 is a widely used measure of health and wellbeing, including two main domains, mental and physical component summary (MCS and PCS respectively), that investigates 8 different areas of perceived health, such as physical functioning, physical role, bodily pain, general health, vitality, social functioning, emotional role and mental health. Scores range from "0 to 100" where "0" indicates the worst condition and "100" indicates the best possible condition

4. NSAIDs and/or acetaminophen consumption [Basal time; one month; three months; six months]

The acetaminophen and NSAIDs/COX-2 inhibitors consumption was calculated asking the patients at each visit the number of tablets taken weekly.

Crystalline Glucosamine Sulfate Therapy in Hand Osteoarthritis

キーワード

oxygenase

glucosamine sulfate

inflammation

osteoarthritis

glucosamine

抗炎症薬

概要

日付

状態または病気

介入/治療

段階

アームグループ

適格基準

結果

科学に裏打ちされた最も完全な薬草データベース